Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Dec, 2015 | Pages:
498 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2015 Summary Global Markets Direct's, 'Amyotrophic Lateral Sclerosis - Pipeline Review, H2 2015', provides an overview of the Amyotrophic Lateral Sclerosis's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Amyotrophic Lateral Sclerosis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Amyotrophic Lateral Sclerosis and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Amyotrophic Lateral Sclerosis - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Amyotrophic Lateral Sclerosis and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Amyotrophic Lateral Sclerosis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Amyotrophic Lateral Sclerosis pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to Buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Amyotrophic Lateral Sclerosis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Amyotrophic Lateral Sclerosis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 Introduction 7 Amyotrophic Lateral Sclerosis Overview 8 Therapeutics Development 9 Amyotrophic Lateral Sclerosis - Therapeutics under Development by Companies 11 Amyotrophic Lateral Sclerosis - Therapeutics under Investigation by Universities/Institutes 20 Amyotrophic Lateral Sclerosis - Pipeline Products Glance 22 Amyotrophic Lateral Sclerosis - Products under Development by Companies 26 Amyotrophic Lateral Sclerosis - Products under Investigation by Universities/Institutes 34 Amyotrophic Lateral Sclerosis - Companies Involved in Therapeutics Development 38 Amyotrophic Lateral Sclerosis - Therapeutics Assessment 118 Drug Profiles 135 Amyotrophic Lateral Sclerosis - Recent Pipeline Updates 383 Amyotrophic Lateral Sclerosis - Dormant Projects 458 Amyotrophic Lateral Sclerosis - Discontinued Products 467 Amyotrophic Lateral Sclerosis - Product Development Milestones 469 Appendix 477
List of Tables
Number of Products under Development for Amyotrophic Lateral Sclerosis, H2 2015 29 Number of Products under Development for Amyotrophic Lateral Sclerosis - Comparative Analysis, H2 2015 30 Number of Products under Development by Companies, H2 2015 32 Number of Products under Development by Companies, H2 2015 (Contd..1) 33 Number of Products under Development by Companies, H2 2015 (Contd..2) 34 Number of Products under Development by Companies, H2 2015 (Contd..3) 35 Number of Products under Development by Companies, H2 2015 (Contd..4) 36 Number of Products under Development by Companies, H2 2015 (Contd..5) 37 Number of Products under Development by Companies, H2 2015 (Contd..6) 38 Number of Products under Development by Companies, H2 2015 (Contd..7) 39 Number of Products under Investigation by Universities/Institutes, H2 2015 41 Comparative Analysis by Late Stage Development, H2 2015 42 Comparative Analysis by Clinical Stage Development, H2 2015 43 Comparative Analysis by Early Stage Development, H2 2015 44 Comparative Analysis by Unknown Stage Development, H2 2015 45 Products under Development by Companies, H2 2015 46 Products under Development by Companies, H2 2015 (Contd..1) 47 Products under Development by Companies, H2 2015 (Contd..2) 48 Products under Development by Companies, H2 2015 (Contd..3) 49 Products under Development by Companies, H2 2015 (Contd..4) 50 Products under Development by Companies, H2 2015 (Contd..5) 51 Products under Development by Companies, H2 2015 (Contd..6) 52 Products under Development by Companies, H2 2015 (Contd..7) 53 Products under Investigation by Universities/Institutes, H2 2015 54 Products under Investigation by Universities/Institutes, H2 2015 (Contd..1) 55 Products under Investigation by Universities/Institutes, H2 2015 (Contd..2) 56 Products under Investigation by Universities/Institutes, H2 2015 (Contd..3) 57 Amyotrophic Lateral Sclerosis - Pipeline by 2-BBB Medicines BV, H2 2015 58 Amyotrophic Lateral Sclerosis - Pipeline by AB Science SA, H2 2015 59 Amyotrophic Lateral Sclerosis - Pipeline by Aestus Therapeutics, Inc., H2 2015 60 Amyotrophic Lateral Sclerosis - Pipeline by Anavex Life Sciences Corp., H2 2015 61 Amyotrophic Lateral Sclerosis - Pipeline by Angion Biomedica Corp., H2 2015 62 Amyotrophic Lateral Sclerosis - Pipeline by Apodemus AB, H2 2015 63 Amyotrophic Lateral Sclerosis - Pipeline by Apogenix GmbH, H2 2015 64 Amyotrophic Lateral Sclerosis - Pipeline by Apotex, Inc., H2 2015 65 Amyotrophic Lateral Sclerosis - Pipeline by ArmaGen,Inc., H2 2015 66 Amyotrophic Lateral Sclerosis - Pipeline by BioCrea GmbH, H2 2015 67 Amyotrophic Lateral Sclerosis - Pipeline by Biogen, Inc., H2 2015 68 Amyotrophic Lateral Sclerosis - Pipeline by BrainStorm Cell Therapeutics Inc., H2 2015 69 Amyotrophic Lateral Sclerosis - Pipeline by CalAsia Pharmaceuticals, Inc., H2 2015 70 Amyotrophic Lateral Sclerosis - Pipeline by Calico LLC, H2 2015 71 Amyotrophic Lateral Sclerosis - Pipeline by Catabasis Pharmaceuticals, Inc., H2 2015 72 Amyotrophic Lateral Sclerosis - Pipeline by Cellceutix Corporation, H2 2015 73 Amyotrophic Lateral Sclerosis - Pipeline by Chronos Therapeutics Limited, H2 2015 74 Amyotrophic Lateral Sclerosis - Pipeline by Cytokinetics, Inc., H2 2015 75 Amyotrophic Lateral Sclerosis - Pipeline by Daval International Limited, H2 2015 76 Amyotrophic Lateral Sclerosis - Pipeline by Edison Pharmaceuticals, Inc., H2 2015 77 Amyotrophic Lateral Sclerosis - Pipeline by Eisai Co., Ltd., H2 2015 78 Amyotrophic Lateral Sclerosis - Pipeline by Evotec AG, H2 2015 79 Amyotrophic Lateral Sclerosis - Pipeline by F. Hoffmann-La Roche Ltd., H2 2015 80 Amyotrophic Lateral Sclerosis - Pipeline by Genervon Biopharmaceuticals, LLC, H2 2015 81 Amyotrophic Lateral Sclerosis - Pipeline by GeNeuro SA, H2 2015 82 Amyotrophic Lateral Sclerosis - Pipeline by GenKyoTex S.A., H2 2015 83 Amyotrophic Lateral Sclerosis - Pipeline by GlaxoSmithKline Plc, H2 2015 84 Amyotrophic Lateral Sclerosis - Pipeline by Glialogix, Inc., H2 2015 85 Amyotrophic Lateral Sclerosis - Pipeline by Grifols, S.A., H2 2015 86 Amyotrophic Lateral Sclerosis - Pipeline by Herantis Pharma Plc, H2 2015 87 Amyotrophic Lateral Sclerosis - Pipeline by ImStar Therapeutics Inc., H2 2015 88 Amyotrophic Lateral Sclerosis - Pipeline by IntelliCell BioSciences Inc., H2 2015 89 Amyotrophic Lateral Sclerosis - Pipeline by Isis Pharmaceuticals, Inc., H2 2015 90 Amyotrophic Lateral Sclerosis - Pipeline by Jeil Pharmaceutical Co., Ltd., H2 2015 91 Amyotrophic Lateral Sclerosis - Pipeline by Kadimastem Ltd., H2 2015 92 Amyotrophic Lateral Sclerosis - Pipeline by Karyopharm Therapeutics, Inc., H2 2015 93 Amyotrophic Lateral Sclerosis - Pipeline by KineMed, Inc., H2 2015 94 Amyotrophic Lateral Sclerosis - Pipeline by Kringle Pharma, Inc., H2 2015 95 Amyotrophic Lateral Sclerosis - Pipeline by Kyorin Pharmaceutical Co., Ltd., H2 2015 96 Amyotrophic Lateral Sclerosis - Pipeline by Kyowa Hakko Kirin Co., Ltd., H2 2015 97 Amyotrophic Lateral Sclerosis - Pipeline by Lascco SA, H2 2015 98 Amyotrophic Lateral Sclerosis - Pipeline by Lead Discovery Center GmbH, H2 2015 99 Amyotrophic Lateral Sclerosis - Pipeline by Maas Biolab, H2 2015 100 Amyotrophic Lateral Sclerosis - Pipeline by Mallinckrodt Plc, H2 2015 101 Amyotrophic Lateral Sclerosis - Pipeline by miCure Therapeutics Ltd., H2 2015 102 Amyotrophic Lateral Sclerosis - Pipeline by miRagen Therapeutics, Inc., H2 2015 103 Amyotrophic Lateral Sclerosis - Pipeline by MitoDys Therapeutics Limited, H2 2015 104 Amyotrophic Lateral Sclerosis - Pipeline by Mitsubishi Tanabe Pharma Corporation, H2 2015 105 Amyotrophic Lateral Sclerosis - Pipeline by Neuralstem, Inc., H2 2015 106 Amyotrophic Lateral Sclerosis - Pipeline by Neuraltus Pharmaceuticals, Inc., H2 2015 107 Amyotrophic Lateral Sclerosis - Pipeline by Neurimmune Holding AG, H2 2015 108 Amyotrophic Lateral Sclerosis - Pipeline by Neurodyn Inc., H2 2015 109 Amyotrophic Lateral Sclerosis - Pipeline by Neurotec Pharma SL, H2 2015 110 Amyotrophic Lateral Sclerosis - Pipeline by Neurotune AG, H2 2015 111 Amyotrophic Lateral Sclerosis - Pipeline by Nexgenix Pharmaceuticals, LLC, H2 2015 112 Amyotrophic Lateral Sclerosis - Pipeline by Orion Oyj, H2 2015 113 Amyotrophic Lateral Sclerosis - Pipeline by Orphazyme ApS, H2 2015 114 Amyotrophic Lateral Sclerosis - Pipeline by Oxford BioMedica Plc, H2 2015 115 Amyotrophic Lateral Sclerosis - Pipeline by Pharnext SAS, H2 2015 116 Amyotrophic Lateral Sclerosis - Pipeline by Primary Peptides, Inc., H2 2015 117 Amyotrophic Lateral Sclerosis - Pipeline by ProMIS Neurosciences Inc., H2 2015 118 Amyotrophic Lateral Sclerosis - Pipeline by Q Therapeutics, Inc., H2 2015 119 Amyotrophic Lateral Sclerosis - Pipeline by ReceptoPharm, Inc., H2 2015 120 Amyotrophic Lateral Sclerosis - Pipeline by Regenesance BV, H2 2015 121 Amyotrophic Lateral Sclerosis - Pipeline by reMYND NV, H2 2015 122 Amyotrophic Lateral Sclerosis - Pipeline by RhinoCyte, Inc., H2 2015 123 Amyotrophic Lateral Sclerosis - Pipeline by RXi Pharmaceuticals Corporation, H2 2015 124 Amyotrophic Lateral Sclerosis - Pipeline by Saneron CCEL Therapeutics, Inc., H2 2015 125 Amyotrophic Lateral Sclerosis - Pipeline by SciFluor Life Sciences, LLC, H2 2015 126 Amyotrophic Lateral Sclerosis - Pipeline by SK Biopharmaceuticals Co., Ltd., H2 2015 127 Amyotrophic Lateral Sclerosis - Pipeline by Spherium Biomed S.L., H2 2015 128 Amyotrophic Lateral Sclerosis - Pipeline by Teva Pharmaceutical Industries Limited, H2 2015 129 Amyotrophic Lateral Sclerosis - Pipeline by Treeway BV, H2 2015 130 Amyotrophic Lateral Sclerosis - Pipeline by UCB S.A., H2 2015 131 Amyotrophic Lateral Sclerosis - Pipeline by uniQure N.V., H2 2015 132 Amyotrophic Lateral Sclerosis - Pipeline by Valeant Pharmaceuticals International, Inc., H2 2015 133 Amyotrophic Lateral Sclerosis - Pipeline by Varinel, Inc., H2 2015 134 Amyotrophic Lateral Sclerosis - Pipeline by ViroMed Co., Ltd., H2 2015 135 Amyotrophic Lateral Sclerosis - Pipeline by Voyager Therapeutics, Inc., H2 2015 136 Amyotrophic Lateral Sclerosis - Pipeline by Yooyoung Pharmaceutical Co., Ltd., H2 2015 137 Assessment by Monotherapy Products, H2 2015 138 Assessment by Combination Products, H2 2015 139 Number of Products by Stage and Target, H2 2015 141 Number of Products by Stage and Mechanism of Action, H2 2015 147 Number of Products by Stage and Route of Administration, H2 2015 152 Number of Products by Stage and Molecule Type, H2 2015 154 Amyotrophic Lateral Sclerosis Therapeutics - Recent Pipeline Updates, H2 2015 403 Amyotrophic Lateral Sclerosis - Dormant Projects, H2 2015 478 Amyotrophic Lateral Sclerosis - Dormant Projects (Contd..1), H2 2015 479 Amyotrophic Lateral Sclerosis - Dormant Projects (Contd..2), H2 2015 480 Amyotrophic Lateral Sclerosis - Dormant Projects (Contd..3), H2 2015 481 Amyotrophic Lateral Sclerosis - Dormant Projects (Contd..4), H2 2015 482 Amyotrophic Lateral Sclerosis - Dormant Projects (Contd..5), H2 2015 483 Amyotrophic Lateral Sclerosis - Dormant Projects (Contd..6), H2 2015 484 Amyotrophic Lateral Sclerosis - Dormant Projects (Contd..7), H2 2015 485 Amyotrophic Lateral Sclerosis - Dormant Projects (Contd..8), H2 2015 486 Amyotrophic Lateral Sclerosis - Discontinued Products, H2 2015 487 Amyotrophic Lateral Sclerosis - Discontinued Products (Contd..1), H2 2015 488
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
